The reiteration of a Buy rating and a maintained price target of $20 by a reputable analyst firm like B. Riley Securities could positively influence investor sentiment towards Altimmune. This endorsement reaffirms the firm's confidence in Altimmune's potential, likely encouraging both current and potential investors about the stock's future performance.